

Clinical Phase 1 Development of BVAC-E6E7 for HPV16 and/or HPV18 Positive Unresectable Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma



ONCOLOGY Phase 1

Product Type	Cell therapies
Indication	HPV 16 and/or 18 positive Head and Neck Squamous Cell Carcinoma
Target	HPV 16 and/or 18 E6, E7 protein
MoA (Mechanism of Action)	<p>BVAC-E6E7 is an immunotherapeutic vaccine manufactured from the patient's peripheral blood mononuclear cells. Following administration, BVAC-E6E7 activates both the NK/NKT cell responses and the HPV specific CD4/CD8 T cell responses, representing innate and adaptive immune responses, respectively. These adaptive and innate immune responses elicit tumor killing effect against both antigen positive tumors and MHC negative tumors.</p>
Competitiveness	HPV positive HNSCC treatment currently involves non-specific therapies, such as immune checkpoint inhibitors. No HPV-specific therapies are approved, and competing drugs (ex. PDS0101 from PDS Biotechnology) have progressed up to Phase 2 clinical trials at most.
Development Stage	Phase 1
Route of Administration	Intravenous administration

Any unauthorized distribution or reproduction of this material is strictly prohibited.